ID

42885

Description

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT00957320

Link

https://clinicaltrials.gov/show/NCT00957320

Keywords

  1. 12/21/15 12/21/15 -
  2. 9/17/21 9/17/21 -
Uploaded on

September 17, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Acute Lymphoblastic Leukemia NCT00957320

Eligibility Acute Lymphoblastic Leukemia NCT00957320

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
less than 21 years old.
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
acute lymphoblastic leukemia.
Description

all

Data type

boolean

Alias
UMLS CUI [1]
C0023449
second or greater bone marrow relapse or 1st relapse and refractory to at least 2 attempts at re-induction.
Description

recurrent disease

Data type

boolean

Alias
UMLS CUI [1]
C0277556
life expectancy of at least 8 weeks.
Description

life expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
fully recovered from the acute toxic effects of all prior therapy.
Description

fully recovered from the acute toxic effects

Data type

boolean

Alias
UMLS CUI [1,1]
C2826210
UMLS CUI [1,2]
C1514463
appropriate organ function.
Description

organ function

Data type

boolean

Alias
UMLS CUI [1]
C0678852
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with a documented history of ≥ grade 3 local or systemic reactions to peg-asparaginase.
Description

allergy to peg-asparaginase

Data type

boolean

Alias
UMLS CUI [1]
C0020517
UMLS CUI [2]
C0071568
patients with a documented history of anti-e. coli asparaginase antibodies.
Description

anti-e. coli asparaginase antibodies

Data type

boolean

Alias
UMLS CUI [1]
C0003241
UMLS CUI [2]
C0003993
patients with a history of ≥ grade 3 pancreatitis.
Description

pancreatitis

Data type

boolean

Alias
UMLS CUI [1]
C0030305
patients with an active and uncontrolled infection.
Description

infection

Data type

boolean

Alias
UMLS CUI [1]
C0009450
patients s/p allogeneic bone marrow transplantation, who are still on immunosuppressants.
Description

patients s/p allogeneic bone marrow transplantation, who are still on immunosuppressants

Data type

boolean

Alias
UMLS CUI [1]
C0085393
UMLS CUI [2]
C0149615
pregnant or lactating females. women of childbearing age will agree to use contraception during the protocol.
Description

pregnant or breastfeeding, contraception

Data type

boolean

Alias
UMLS CUI [1]
C0549206
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0700589
patients currently receiving other investigational agents, medications, or supplements with a known anti-leukemic effect.
Description

study subject participation status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
other concomitant medications that may alter the metabolism of sirolimus (see section 7.2).
Description

other concomitant medications

Data type

boolean

Alias
UMLS CUI [1]
C2347852
patients who, in the opinion of the investigator, will not be able to comply with safety monitoring requirements of the study.
Description

patients who, in the opinion of the investigator, will not be able to comply

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
patients with a history of a documented thrombus from previous asparaginase therapy.
Description

thrombus from previous asparaginase therapy

Data type

boolean

Alias
UMLS CUI [1]
C0087086
UMLS CUI [2]
C3548803

Similar models

Eligibility Acute Lymphoblastic Leukemia NCT00957320

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
age
Item
less than 21 years old.
boolean
C0001779 (UMLS CUI [1])
all
Item
acute lymphoblastic leukemia.
boolean
C0023449 (UMLS CUI [1])
recurrent disease
Item
second or greater bone marrow relapse or 1st relapse and refractory to at least 2 attempts at re-induction.
boolean
C0277556 (UMLS CUI [1])
life expectancy
Item
life expectancy of at least 8 weeks.
boolean
C0023671 (UMLS CUI [1])
fully recovered from the acute toxic effects
Item
fully recovered from the acute toxic effects of all prior therapy.
boolean
C2826210 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
organ function
Item
appropriate organ function.
boolean
C0678852 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
allergy to peg-asparaginase
Item
patients with a documented history of ≥ grade 3 local or systemic reactions to peg-asparaginase.
boolean
C0020517 (UMLS CUI [1])
C0071568 (UMLS CUI [2])
anti-e. coli asparaginase antibodies
Item
patients with a documented history of anti-e. coli asparaginase antibodies.
boolean
C0003241 (UMLS CUI [1])
C0003993 (UMLS CUI [2])
pancreatitis
Item
patients with a history of ≥ grade 3 pancreatitis.
boolean
C0030305 (UMLS CUI [1])
infection
Item
patients with an active and uncontrolled infection.
boolean
C0009450 (UMLS CUI [1])
patients s/p allogeneic bone marrow transplantation, who are still on immunosuppressants
Item
patients s/p allogeneic bone marrow transplantation, who are still on immunosuppressants.
boolean
C0085393 (UMLS CUI [1])
C0149615 (UMLS CUI [2])
pregnant or breastfeeding, contraception
Item
pregnant or lactating females. women of childbearing age will agree to use contraception during the protocol.
boolean
C0549206 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
study subject participation status
Item
patients currently receiving other investigational agents, medications, or supplements with a known anti-leukemic effect.
boolean
C2348568 (UMLS CUI [1])
other concomitant medications
Item
other concomitant medications that may alter the metabolism of sirolimus (see section 7.2).
boolean
C2347852 (UMLS CUI [1])
patients who, in the opinion of the investigator, will not be able to comply
Item
patients who, in the opinion of the investigator, will not be able to comply with safety monitoring requirements of the study.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
thrombus from previous asparaginase therapy
Item
patients with a history of a documented thrombus from previous asparaginase therapy.
boolean
C0087086 (UMLS CUI [1])
C3548803 (UMLS CUI [2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial